Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Acquired Resistance to a MET Antibody Can Be Overcome by the MET Antibody Mixture Sym015

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Proteomics of cancer cell lines resistant to microtubule-stabilizing agents

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. 123I-MIBG for detection of subacute doxorubicin-induced cardiotoxicity in patients with malignant lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Soluble Markers of Interleukin 1 Activation as Predictors of First-Time Myocardial Infarction in HIV-Infected Individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. FDG-PET/CT in the surveillance of head and neck cancer following radiotherapy

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Failure of clinical trials due to development of resistance to MET-targeting therapeutic agents is an emerging problem. Mechanisms of acquired resistance to MET tyrosine kinase inhibitors are well described, whereas characterization of mechanisms of resistance toward MET-targeting antibodies is limited. This study investigated mechanisms underlying in vivo resistance to two antibody therapeutics currently in clinical development: an analogue of the MET-targeting antibody emibetuzumab and Sym015, a mixture of two antibodies targeting nonoverlapping epitopes of MET. Upon long-term in vivo treatment of a MET-amplified gastric cancer xenograft model (SNU-5), emibetuzumab-resistant, but not Sym015-resistant, tumors emerged. Resistant tumors were isolated and used to establish resistant cell lines. Characterization of both tumors and cell lines using extensive protein and signaling pathway activation mapping along with next-generation sequencing revealed two distinct resistance profiles, one involving PTEN loss and the other involving activation of the PI3K pathway, likely via MYC and ERBB3 copy number gains. PTEN loss left one model unaffected by PI3K/AKT targeting but sensitive to mTOR targeting, while the PI3K pathway-activated model was partly sensitive to targeting of multiple PI3K pathway proteins. Importantly, both resistant models were sensitive to treatment with Sym015 in vivo due to antibody-dependent cellular cytotoxicity-mediated tumor growth inhibition, MET degradation, and signaling inhibition. Taken together, our data provide key insights into potential mechanisms of resistance to a single MET-targeting antibody, demonstrate superiority of Sym015 in preventing acquired resistance, and confirm Sym015 antitumor activity in tumors resistant to a single MET antibody. Mol Cancer Ther; 17(6); 1259-70. ©2018 AACR.

Original languageEnglish
JournalMolecular Cancer Therapeutics
Volume17
Issue number6
Pages (from-to)1259-1270
Number of pages12
ISSN1535-7163
DOIs
Publication statusPublished - Jun 2018

ID: 55063796